3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Multiple Myeloma
7
Prostatic Neoplasms
3
Lymphoma
3
Plasmacytoma
2
Paraproteinemias
2
Neoplasms
2
Neoplasm Metastasis
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Leukemia, Plasma Cell
2
Breast Neoplasms
2
Anatomic Stage IV Breast Cancer AJCC v8
2
Spinal Cord Compression
1
Recurrence
1
Radiation Injuries
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms, Germ Cell and Embryonal
1
Nasopharyngeal Carcinoma
1
Myasthenia Gravis
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hepatitis
1
Hemangioma
1
Head and Neck Neoplasms
1
Glioma
1
Gallstones
1
Esophageal Stenosis
1
Interventions
bavituximab
1
Ursodeoxycholic Acid
1
Steroids
1
Sorafenib
1
Sofosbuvir
1
Ribavirin
1
Prednisone
1
Mycophenolic Acid
1
Methylprednisolone Hemisuccinate
1
Methylprednisolone
1
Adrenal Cortex Hormones
1
3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Hepatitis
×
Steroids
×
Clear all
NCT04810156
2022-12-14
I-HEP
Herlev Hospital
Phase 2
Unknown
60 enrolled